taxane + mitoxantrone + thiotepa

A combination chemotherapy regimen comprised of a **taxane** (such as docetaxel or paclitaxel), **mitoxantrone**, and **thiotepa**, most commonly evaluated in high-dose chemotherapy or salvage therapy for metastatic breast cancer and potentially other advanced malignancies. - **Taxanes** (e.g., docetaxel, paclitaxel) are microtubule inhibitors that disrupt cell division by stabilizing tubulin, thus inhibiting microtubule depolymerization and halting mitosis. - **Mitoxantrone** is an anthracenedione that intercalates into DNA and inhibits topoisomerase II, resulting in DNA damage and cell death. - **Thiotepa** is an alkylating agent that cross-links DNA, preventing cell replication and leading to apoptosis. This combination is researched primarily as part of high-dose regimens for treatment-refractory or metastatic cancers, especially **breast cancer**. The regimen is associated with potent myelosuppression and requires specialized supportive care.